Key facts
- Alpa Life Bio’s last known valuation is $44.5M (Dec 2022).
- It has raised $16.1M; the latest was Later Stage VC ($9.8M) in Sep 2025.
- Notable investors include Jolmo Investment, C2I Accelerator, Dianke Internet Research Institute, Galaxy Ventures (China), Nanling Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Alpa Life Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Alpa Life Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alpa Life Bio
Provider of nanobody drug discovery services focused on GPCRs and other target proteins for pharmaceutical research. The company specailises in phage and yeast display platforms, nanobody screening systems, functional validation assays, automated fermentation systems and alpaca-based antibody generation, thereby accelerating therapeutic development and supporting global biopharmaceutical innovation.
- Sector
- Business Products and Services (B2B)
- HQ
- Shenzhen, China
- Founded
- 2016
- Employees
- 100
- Website
- ktsm-life.com/
- Ownership
- Privately Held (backing)
Alpa Life Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alpa Life Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alpa Life Bio in its N-PORT filings yet. We sweep new filings monthly.